Loading organizations...
Gemini Therapeutics is a Cambridge, Massachusetts-based clinical-stage biotechnology company focused on developing precision medicines for genetically linked diseases, particularly age-related macular degeneration and oncology. The company advanced its lead therapeutic candidate, GEM103, for dry AMD and previously developed aldoxorubicin as a single-asset entity before undergoing significant operational restructuring. After going public in October 2020 through a SPAC merger with a vehicle backed by Foresite Capital, the firm executed a reverse merger with Disc Medicine in late 2022. Following the transaction, Disc Medicine shareholders retained a 72% ownership stake in the combined public entity, while Gemini implemented severe workforce reductions, cutting 20% of its staff followed by an 80% reduction of the remaining employees. Supported by early institutional investors like Even One Ventures, Gemini Therapeutics was originally founded in 2015 by Andy Herbert and Sant Chawla.
Gemini Therapeutics has raised $45.0M across 2 funding rounds.
Gemini Therapeutics has raised $45.0M in total across 2 funding rounds.
Gemini Therapeutics has raised $45.0M in total across 2 funding rounds.
Gemini Therapeutics's investors include Atlas Venture, OrbiMed, Jean George, Access Biotechnology, Advanced Technology Ventures, Avoro Ventures, Chris, Frazier Healthcare Partners, Longwood Fund, The Column Group, Versant Ventures.
Gemini Therapeutics has raised $45.0M across 2 funding rounds. Most recently, it raised $43.0M Series A in October 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2017 | $43M Series A | Atlas Venture, OrbiMed, Jean George | Access Biotechnology, Advanced Technology Ventures, Avoro Ventures, Chris, Frazier Healthcare Partners, Longwood Fund, The Column Group, Versant Ventures | Announced |
| Apr 1, 2016 | $2M Seed | — | Access Biotechnology, Advanced Technology Ventures, Atlas Venture, Avoro Ventures, Chris, Frazier Healthcare Partners, Longwood Fund, OrbiMed, The Column Group, Versant Ventures | Announced |
Gemini Therapeutics is a clinical-stage biotechnology company, not a general technology firm, specializing in precision medicine for genetically defined diseases, primarily dry age-related macular degeneration (AMD) and related rare eye disorders.[1][2][3] It develops therapies like recombinant proteins, gene therapies, and monoclonal antibodies targeting complement system dysregulation, serving patients with high unmet needs in ophthalmology, such as those with complement factor H (CFH) variants affecting ~40% of dry AMD cases (6 million patients globally).[1][2] The lead product, GEM103—a recombinant CFH protein—was in Phase 2a trials for dry AMD but has since been discontinued, alongside other pipeline candidates like GEM-307 and various gene therapies; the company invested ~$50 million in R&D in 2024 across AMD, Stargardt Disease, and Retinitis Pigmentosa targets.[1][3] Growth momentum included a 2021 public debut via SPAC merger, but recent developments show pipeline setbacks with multiple discontinuations.[2][3][5]
Founded in 2015 and headquartered in Cambridge, Massachusetts, Gemini Therapeutics emerged to tackle genetic drivers of serious diseases, particularly in ophthalmology.[1][6] Key leadership included CEO Jason Meyenburg, who highlighted the SPAC merger with FS Development Corp. in 2021 as a pivotal moment to access public markets and advance complement-focused precision medicines.[2] The idea stemmed from identifying molecular abnormalities in high-need patients, leading to a multimodal pipeline; early traction built around GEM103's targeted approach for CFH-variant AMD patients, culminating in Phase 2a initiation by 2021.[2][3] The company evolved from private biotech to publicly traded (Nasdaq: GMTX) via the SPAC, emphasizing trial enrichment with genetically defined cohorts.[2][5]
Gemini rides the precision medicine wave in biotech, leveraging genetic profiling to address unmet needs in age-related diseases amid an aging global population driving AMD prevalence (15 million dry AMD cases).[1][2] Timing aligns with advances in gene therapy and complement biology, fueled by market forces like rising ophthalmology demand and regulatory nods for targeted therapies (e.g., post-2020 trial accelerations).[3] It influences the ecosystem by validating genetically enriched trials, partnering (e.g., StrideBio), and contributing to complement-targeted innovation, though discontinuations highlight biotech risks in high-failure fields like rare diseases.[2][3][6]
Pipeline discontinuations (e.g., GEM103, gene therapies) signal challenges, potentially shifting Gemini toward repivoting its precision platform or acquisition amid biotech funding pressures.[3][5] Trends like AI-driven genetics and next-gen complement inhibitors could revive momentum if leveraged, evolving its role from AMD pioneer to broader rare disease player. As a public entity post-SPAC, strategic partnerships or pipeline reboots will define influence, tying back to its mission of genetic breakthroughs for serious diseases.[1][2]
